ADC Therapeutics (NYSE:ADCT) traded higher on Thursday after announcing data from a Phase 1b trial designed to study its antibody-drug conjugate, Zynlonta, in combination with bispecific antibodies as...
Source LinkADC Therapeutics (NYSE:ADCT) traded higher on Thursday after announcing data from a Phase 1b trial designed to study its antibody-drug conjugate, Zynlonta, in combination with bispecific antibodies as...
Source Link
Comments